Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma.

Kinome-wide CRISPR-Cas9 knockout screens revealed PLK1 as a therapeutic target for osteosarcoma.
复制标题

全kinome CRISPR-Cas9敲除筛选显示PLK1是骨肉瘤的治疗靶点。

DOI:
10.1038/s41420-023-01526-7
复制
发表时间:
2023-07-07
影响因子:
7
通讯作者:
Liang, Junbo
Liang, Junbo
中科院分区:
医学2区
文献类型:
--
作者:
Wang, Renxian;Wang, Dingding;Bai, Xueshan;Guo, Jianxun;Xia, Songxia;Cheng, Yuning;Gu, Yani;Wang, Qian;Nie, Jingjun;Chen, Dafu;Liu, Weifeng;Liang, Junbo

文献摘要

参考文献

相似文献

骨肉瘤是最常见的恶性骨肿瘤,具有侵袭性强、易复发的特点。由于缺乏有效和特异性的靶点,骨肉瘤的治疗进展受到很大阻碍。使用全激酶组CRISPR-Cas9敲除筛选,我们系统地揭示了一组对人类骨肉瘤细胞的生存和生长至关重要的激酶,其中Polo样激酶1(PLK 1)似乎是一个特定的突出命中。PLK 1基因敲除可显著抑制骨肉瘤细胞的体外增殖和骨肉瘤异种移植瘤的体内生长。Volasertib是一种有效的实验性PLK 1抑制剂,在体外可有效抑制骨肉瘤细胞系的生长。它还可以破坏体内患者来源的异种移植物(PDX)模型中肿瘤的发展。此外,我们证实volasertib的作用模式(MoA)主要由DNA损伤引发的细胞周期阻滞和细胞凋亡介导。随着PLK 1抑制剂进入III期临床试验,我们的发现为对抗骨肉瘤的相关治疗方法的疗效和MoA提供了重要的见解。
Osteosarcoma is the most common malignant bone tumor, tending to be aggressive and recurrent. The therapeutic development for treating osteosarcoma has been largely hampered by the lack of effective and specific targets. Using kinome-wide CRISPR-Cas9 knockout screens, we systematically revealed a cohort of kinases essential for the survival and growth of human osteosarcoma cells, in which Polo-like kinase 1 (PLK1) appeared as a specific prominent hit. PLK1 knockout substantially inhibited proliferation of osteosarcoma cells in vitro and the tumor growth of osteosarcoma xenograft in vivo. Volasertib, a potent experimental PLK1 inhibitor, can effectively inhibit the growth of the osteosarcoma cell lines in vitro. It can also disrupt the development of tumors in the patient-derived xenograft (PDX) models in vivo. Furthermore, we confirmed that the mode of action (MoA) of volasertib is primarily mediated by the cell-cycle arrest and apoptosis triggered by DNA damage. As PLK1 inhibitors are entering phase III clinical trials, our findings provide important insights into the efficacy and MoA of the relevant therapeutic approach for combating osteosarcoma.
DOI: 10.1158/1535-7163.mct-15-0897
发表时间: 2016-07
影响因子: 5.7
作者:
Gutteridge RE;Ndiaye MA;Liu X;Ahmad N
通讯作者: Ahmad N
DOI: 10.1038/bjc.2014.195
发表时间: 2014-05-13
影响因子: 8.8
作者:
Lin, C-C;Su, W-C;Yen, C-J;Hsu, C-H;Su, W-P;Yeh, K-H;Lu, Y-S;Cheng, A-L;Huang, D. C-L;Fritsch, H.;Voss, F.;Taube, T.;Yang, J. C-H
通讯作者: Yang, J. C-H
DOI: 10.1038/nbt.3437
发表时间: 2016-02
影响因子: 46.9
作者:
Doench JG;Fusi N;Sullender M;Hegde M;Vaimberg EW;Donovan KF;Smith I;Tothova Z;Wilen C;Orchard R;Virgin HW;Listgarten J;Root DE
通讯作者: Root DE
DOI: 10.4161/15384101.2014.977067
发表时间: 2015
期刊: Cell cycle (Georgetown, Tex.)
影响因子: --
作者:
Benada J;Burdová K;Lidak T;von Morgen P;Macurek L
通讯作者: Macurek L
DOI: 10.1097/cad.0000000000000157
发表时间: 2015-01-01
期刊: ANTI-CANCER DRUGS
影响因子: 2.3
作者:
Bogado, Rodrigo F. E.;Pezuk, Julia A.;Brassesco, Maria S.
通讯作者: Brassesco, Maria S.